肾移植受者从钙调磷酸酶抑制剂转换为贝拉西普后3年安全性与疗效结局:一项2期随机试验结果
该2期随机试验36个月随访显示,低免疫风险肾移植受者从钙调磷酸酶抑制剂(CNI)转换为贝拉西普后,严重不良事件发生率与继续CNI组相似,平均eGFR估计年增益显著更高(1.90 vs 0.07 mL/min/1.73m²/年,交互作用P=0.01),急性排斥反应概率无显著差异(8.38% vs 3.60%;HR 2.50,95%CI 0.65-9.65;P=0.2)。作者认为转换可能是一种安全的免疫抑制策略,正在进行的3b期试验中进一步探索。
要点
- 转换至贝拉西普组与继续CNI组的严重不良事件发生率分别为39%和40%。
- 贝拉西普组平均eGFR估计年增益显著高于CNI组(1.90 vs 0.07 mL/min/1.73m²/年;交互作用P=0.01)。
- 急性排斥反应概率两组无显著差异(8.38% vs 3.60%;HR 2.50,95%CI 0.65-9.65;P=0.2)。
核心结论
- 在低免疫风险肾移植受者中,从CNI转换为贝拉西普可能是一种安全的免疫抑制策略,正在进行的3b期试验中进一步探索。
研究设计与样本
- 36个月随访的意向性治疗人群分析,患者为接受CNI治疗且移植肾功能稳定(eGFR 35-75 mL/min/1.73m²)的成人肾移植受者。
- 移植后6至36个月随机分配至转换为贝拉西普为基础免疫抑制(n=84)或继续CNI为基础治疗(n=89)。
主要发现
- 严重不良事件发生于贝拉西普组33例(39%)和CNI组36例(40%)。
- 严重感染暴露调整发生率贝拉西普组 vs CNI组为10.21 vs 9.31每100人年,恶性肿瘤为3.01 vs 3.41每100人年,两组相似。
- 任何级别病毒感染暴露调整发生率贝拉西普组 vs CNI组为14.60 vs 11.00每100人年,贝拉西普组更高。
- 未报告移植后淋巴增殖性疾病。
- 贝拉西普组平均eGFR估计年增益显著高于CNI组(1.90 vs 0.07 mL/min/1.73m²/年;时间与治疗交互作用P=0.01)。
临床怎么用
- 作者认为,从CNI转换为贝拉西普可能是一种安全的免疫抑制方法。
局限性
- 探索性事后分析,样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In a phase 2 study, kidney transplant recipients of low immunologic risk who switched from a calcineurin inhibitor (CNI) to belatacept had improved kidney function at 12 months postconversion versus those continuing CNI therapy, with a low rate of acute rejection and no transplant loss. STUDY DESIGN: 36-month follow-up of the intention-to-treat population. SETTING & PARTICIPANTS: CNI-treated adult kidney transplant recipients with stable transplant function (estimated glomerular filtration rate [eGFR], 35-75mL/min/1.73m2). INTERVENTIONS: At 6 to 36 months posttransplantation, patients were randomly assigned to switch to belatacept-based immunosuppression (n=84) or continue CNI-based therapy (n=89). OUTCOMES: Safety was the primary outcome. eGFR, acute rejection, transplant loss, and death were also assessed. MEASUREMENTS: Treatment exposure-adjusted incidence rates for safety, repeated-measures modeling for eGFR, Kaplan-Meier analyses for efficacy. RESULTS: Serious adverse events occurred in 33 (39%) belatacept-treated patients and 36 (40%) patients in the CNI group. Treatment exposure-adjusted incidence rates for serious infections (belatacept vs CNI, 10.21 vs 9.31 per 100 person-years) and malignancies (3.01 vs 3.41 per 100 person-years) were similar. More patients in the belatacept versus CNI group had any-grade viral infections (14.60 vs 11.00 per 100 person-years). No posttransplantation lymphoproliferative disorder was reported. Belatacept-treated patients had a significantly greater estimated gain in mean eGFR (1.90 vs 0.07mL/min/1.73m2 per year; P for time-by-treatment interaction effect = 0.01). The probability of acute rejection was not significantly different for belatacept (8.38% vs 3.60%; HR, 2.50 [95% CI, 0.65-9.65; P=0.2). HR for the comparison of belatacept to the CNI group for time to death or transplant loss was 1.00 (95% CI, 0.14-7.07; P=0.9). LIMITATIONS: Exploratory post hoc analysis with a small sample size. CONCLUSIONS: Switching patients from a CNI to belatacept may represent a safe approach to immunosuppression and is being further explored in an ongoing phase 3b trial.
引用
- Grinyó JM, Del Carmen Rial M, Alberu J, et al. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial. Am J Kidney Dis. 2016. PMID: 27889299. doi:10.1053/j.ajkd.2016.09.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。